Original Source(s)
Related Content
Molecular Interplay between hypertension and dyslipidemia in cardiovascular pathogenesis: toward precision-based therapeutic strategies
by Boming Cao, Jingyi Pei, Ling Kong, Ying Han, Guangli Yan, Xijun Wang
June 11, 2026
Investigational Drug Shows Potentialin Phase 3 Obesity Trial
In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.
June 10, 2026
-
4 min
How Quickly Are Patients Reaching Quadruple HFrEF Therapy?
Delays in initiating guideline-directed quadruple therapy may increase early clinical risk in heart failure with reduced ejection fraction.
June 8, 2026
-
5 min